Target intelligence / Profile preview

ATP-sensitive potassium channel subunit Kir6.2 and sulfonylurea receptor 1 (Pancreatic β-cell KATP channel) (KATP channel)

Target
KATP channel
Molecular classification
Ion channel, Potassium channel, Inward-rectifier potassium channel (Kir), ABC transporter family subunit (SUR1)
01

Overview

The pancreatic β-cell KATP channel is a metabolic sensor that couples intracellular ATP/ADP ratios to membrane excitability, composed of four Kir6.2 (inward-rectifier potassium channel) subunits and four SUR1 (sulfonylurea receptor 1) subunits, forming a hetero-octameric ion channel complex. In pancreatic β-cells, closure of this channel in response to rising ATP levels from glucose metabolism leads to membrane depolarization, opening of voltage-gated calcium channels, and subsequent insulin secretion. Mutations in Kir6.2 or SUR1 can cause neonatal diabetes (gain of function) or congenital hyperinsulinism (loss of function), making KATP channels a major therapeutic target for antidiabetic agents such as sulfonylureas and diazoxide. Multiple drugs interact with the channel by either blocking or activating it, critically influencing β-cell function and glucose homeostasis[1][4][5][7].

Other names
ATP-sensitive potassium channelβ-cell KATP channelKir6.2/SUR1 channelKATPKir6.2/SUR1ATP-sensitive K+ channel
02

Mechanism of action

Inhibition (closing) of KATP channels stimulates insulin secretion by depolarizing β-cells (sulfonylureas, meglitinides)[1][2][5] Opening of KATP channels hyperpolarizes cells and suppresses insulin secretion (diazoxide)[7][4]

03

Biological functions

Regulation of insulin secretionCoupling cellular metabolism to electrical activityGlucose sensing in β-cellsControl of plasma membrane excitability
04

Disease associations

Neonatal diabetes mellitusCongenital hyperinsulinismType 2 diabetes mellitusHyperinsulinism
05

Safety considerations

Sulfonylurea-induced hypoglycemiaDiazoxide-induced fluid retention, hypertrichosisRisk of β-cell exhaustion and apoptosis with chronic overactivation or inhibition[6]
06

Interacting drugs

Sulfonylureas (glibenclamide, gliclazide, glimepiride)

3 more in the full profile.

07

Biomarkers

Mutations in KCNJ11 (Kir6.2) and ABCC8 (SUR1) genes for neonatal diabetes and congenital hyperinsulinism[4][8]KATP channel activity for stratifying insulin secretion disorders[3][4]

Beyond the preview

Go deeper on ATP-sensitive potassium channel subunit Kir6.2 and sulfonylurea receptor 1 (Pancreatic β-cell KATP channel) (KATP channel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-sensitive potassium channel subunit Kir6.2 and sulfonylurea receptor 1 (Pancreatic β-cell KATP channel) (KATP channel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call